OnabotulinumtoxinA for Treatment of Moderate-To-Severe Horizontal Lines and Glabellar Lines From the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes From a Phase 3 Double-Blind Study

SKIN The Journal of Cutaneous Medicine

doi 10.25251/skin.1.supp.81

Full Text

Abstract

Available in

Date

October 27, 2017

Authors

Publisher

National Society for Cutaneous Medicine

Related search

OnabotulinumtoxinA Treatment of Moderate to Severe Glabellar Lines in Chinese Subjects After Laser Therapy: A Prospective, Open-Label, Noncomparative Study

Journal of Cosmetic and Laser Therapy

English

Efficacy and Patient Satisfaction With incobotulinumtoxinA for the Treatment of Glabellar Frown Lines

Singapore Medical Journal

Medicine

2017

English

The Psychological Impacts of Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines: Qualitative, Patient-Centered Studies

SKIN The Journal of Cutaneous Medicine

2017

English

Efficacy and Safety of OnabotulinumtoxinA for Moderate-To-Severe Forehead Lines in Subjects With Upper Facial Lines

SKIN The Journal of Cutaneous Medicine

2017

English

Onset, Longevity, and Patient Satisfaction With incobotulinumtoxinA for the Treatment of Glabellar Frown Lines: A Single-Arm, Prospective Clinical Study

Clinical Interventions in Aging

English

Patient-Reported Outcomes From Two Randomized, Double-Blind, Vehicle Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

SKIN The Journal of Cutaneous Medicine

2018

English

Patient-Reported Outcomes in Moderate to Severe Hemophilia Patients: Finding From a Cross-Sectionalstudy in Korea

English

Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician‐ and Patient‐Reported Satisfaction: Long‐Term Observational Results From the ASPIRE Study

English

Patient-Reported Outcomes of Multiple Myeloma Patients Treated With Panobinostat After ≥2 Lines of Therapy Based on the International Phase 3, Randomized, Double-Blind, Placebo-Controlled PANORAMA-1 Trial

British Journal of Haematology

Hematology

2018

English

Amanote Research

OnabotulinumtoxinA for Treatment of Moderate-To-Severe Horizontal Lines and Glabellar Lines From the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes From a Phase 3 Double-Blind Study

SKIN The Journal of Cutaneous Medicine

Full Text

Abstract

Date

Authors

Publisher

Related search

OnabotulinumtoxinA Treatment of Moderate to Severe Glabellar Lines in Chinese Subjects After Laser Therapy: A Prospective, Open-Label, Noncomparative Study

Efficacy and Patient Satisfaction With incobotulinumtoxinA for the Treatment of Glabellar Frown Lines

The Psychological Impacts of Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines: Qualitative, Patient-Centered Studies

Efficacy and Safety of OnabotulinumtoxinA for Moderate-To-Severe Forehead Lines in Subjects With Upper Facial Lines

Onset, Longevity, and Patient Satisfaction With incobotulinumtoxinA for the Treatment of Glabellar Frown Lines: A Single-Arm, Prospective Clinical Study

Patient-Reported Outcomes From Two Randomized, Double-Blind, Vehicle Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

Patient-Reported Outcomes in Moderate to Severe Hemophilia Patients: Finding From a Cross-Sectionalstudy in Korea

Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician‐ and Patient‐Reported Satisfaction: Long‐Term Observational Results From the ASPIRE Study

Patient-Reported Outcomes of Multiple Myeloma Patients Treated With Panobinostat After ≥2 Lines of Therapy Based on the International Phase 3, Randomized, Double-Blind, Placebo-Controlled PANORAMA-1 Trial